BAKER BROS. ADVISORS LP Q3 2019 Filing
Filed November 14, 2019
Portfolio Value
$14.7B
Holdings
109
Report Date
Q3 2019
Filing Type
13F-HR
All Holdings (109 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | —Sierra Oncology, Inc. | 2,000,000 | $781.0M | 5.31% | |
| 102 | INFIQInfinity Pharmaceuticals, Inc. | 580,400 | $598.0M | 4.07% | |
| 103 | —Affimed N.V. | 200,000 | $588.0M | 4.00% | |
| 104 | —Evofem Biosciences, Inc. | 102,048 | $514.0M | 3.50% | |
| 105 | —Sunesis Pharmaceuticals, Inc. | 556,665 | $401.0M | 2.73% | |
| 106 | AQSTAquestive Therapeutics, Inc. | 99,600 | $317.0M | 2.16% | |
| 107 | DVAXDynavax Technologies Corporation | 75,000 | $268.0M | 1.82% | |
| 108 | TREURTrillium Therapeutics Inc. | 505,262 | $155.0M | 1.05% | |
| 109 | —Ritter Pharmaceuticals, Inc. | 279,999 | $87.0M | 0.59% |
PreviousPage 2 of 2